Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Barbone, Dario ^a   Van Dam, Loes ^b   Follo, Carlo ^a   Jithesh, Puthen V ^c   Zhang, Shu Dong ^d   Richards, William G ^e   Bueno, Raphael ^e   Fennell, Dean A ^f   Broaddus, V Courtney ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININOSUCCINATE SYNTHASE 1; BORTEZOMIB; CISPLATIN; LIGASE; LIPOCORTIN 4; LUNG RESISTANCE PROTEIN; MESSENGER RNA; PEMETREXED; UNCLASSIFIED DRUG; ARGININOSUCCINATE SYNTHASE; RIBONUCLEOPROTEIN;

ANXA4 GENE; ARTICLE; ASS1 GENE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MESOTHELIOMA CELL LINE; MONOLAYER CULTURE; MVP GENE; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; TUMOR SPHEROID; UPREGULATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; MESOTHELIOMA; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL LINE;

ANNEXIN A4; ARGININOSUCCINATE SYNTHASE; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; SPHEROIDS, CELLULAR; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 85014577074     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150044     Document Type: Article

References (47)

1. Barbone D, Yang T, Morgan J, Gaudino G, Broaddus V. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem. 2008;283(19):13021-30. PMID: 18339627. doi: 10.1074/jbc. M709698200
2. Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A, et al. Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates. Cell Death Differ. 2009;16(8):1146-55. PMID: 19343038. doi: 10.1038/cdd.2009.32
3. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 1993;53(11):2631-43. PMID: 8495427.
4. Barbone D, Ryan JA, Kolhatkar N, Chacko AD, Jablons DM, Sugarbaker DJ, et al. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. 2011;2:e174. doi: 10.1038/cddis.2011.58 PMID: 21697949; PubMed Central PMCID: PMC3169000.
5. Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, et al. Vorinostateliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One. 2012;7(12):e52753. doi: 10.1371/journal.pone.0052753 PMID: 23300762; PubMed Central PMCID: PMC3530471.
6. Kim H, Phung Y, Ho M. Changes in global gene expression associated with 3D structure of tumors: an ex vivo matrix-free mesothelioma spheroid model. PLoSOne. 2012;7(6):e39556. doi: 10.1371/journal.pone.0039556 PMID: 22737246; PubMed Central PMCID: PMC3380922.
7. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumourtarget. PLoSOne. 2009;4(9):e7016. doi: 10.1371/journal.pone.0007016 PMID: 19753302; PubMed Central PMCID: PMCPMC2737627.
8. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognosticfactors and critical evaluation of microarray-based prognostic PMID: prediction. Cancer Res. 2006;66(6):2970-9. doi: 10.1158/0008-5472. CAN-05-3907 PMID: 16540645.
9. Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, et al. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutat Res. 2011;750(2):132-40. Epub 2011/12/27. doi: 10.1016/j.mrrev. 2011.12.003 PMID: 22198210.
10. Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, et al. Expression status of candidate genes in mesothelioma tissues and cell lines. Mutat Res. 2015;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002 PMID: 25771974.
11. Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264-9. doi: 10.1158/0008-5472. CAN-14-1008 PMID: 25488749.
12. De Rienzo A, Dong L, Yeap BY, Jensen RV, Richards WG, Gordon GJ, et al. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2011;17(2):310-6. doi: 10.1158/1078-0432. CCR-10-0806 PMID: 21088255; PubMed Central PMCID: PMCPMC3058309.
13. Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H, et al. Four-gene expression ratio test forsurvival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101(9):678-86. doi: 10.1093/jnci/djp061 PMID: 19401544; PubMed Central PMCID: PMCPMC2677573.
14. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst. 2003;95(8):598-605. PMID: 12697852.
15. Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN, Yeap BY, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005;11(12):4406-14. doi: 10.1158/1078-0432. CCR-04-2181 PMID: 15958625; PubMed Central PMCID: PMCPMC1488818.
16. Battisti S, Valente D, Albonici L, Bei R, Modesti A, Palumbo C. Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells. Am J RespirCell Mol Biol. 2012;46(4):498-506. doi: 10.1165/rcmb.2011-0195OC PMID: 22074703.
17. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(12):2762-72. Epub 2010/01/28. doi: 10.1002/ijc.25202 PMID: 20104527.
18. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res. 2006;12(23):7126-31. Epub 2006/12/06. doi: 10.1158/1078-0432. CCR-06-1101 PMID: 17145837.
19. Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol. 2013;31(7):e111-3. doi: 10.1200/JCO.2012.42.1784 PMID: 23319692.
20. Wangpaichitr M, Wu C, Bigford G, Theodoropoulos G, You M, Li YY, et al. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. Anticancer Res. 2014;34(12):6991-9. PMID: 25503125.
21. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using largescale transcriptional profiling. Am J Pathol. 2005;166(6):1827-40. Epub 2005/05/28. doi: 10.1016/S0002-9440 (10) 62492-3 PMID: 15920167; PubMed Central PMCID: PMC1363736.
22. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res. 2003;9(8):3080-97. Epub 2003/08/13. PMID: 12912960.
23. Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis. 2013;4:e458. doi: 10.1038/cddis.2012.197 PMID: 23328665; PubMed Central PMCID: PMC3563985.
24. Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 2009;125(6):1454-63. doi: 10.1002/ijc.24546 PMID: 19533750.
25. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009;4(3):309-24. doi: 10.1038/nprot.2008.226 PMID: 19214182.
26. Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, et al. SV40-dependentAKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res. 2005;65(12):5256-62. PMID: 15958571.
27. Pinton G, Manente AG, Angeli G, Mutti L, Moro L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKTaxis in malignant pleural mesothelioma. PLoSOne. 2012;7(5):e36856. doi: 10.1371/journal.pone.0036856 PMID: 22590625; PubMed Central PMCID: PMCPMC3349630.
28. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol. 2004;5(6):354-62. doi: 10.1016/S1470-2045 (04) 01492-5 PMID: 15172356.
29. Sakai Y, Yamagami S, Nakazawa K. Comparative analysis of gene expression in rat liver tissue and monolayer- and spheroid-cultured hepatocytes. Cells Tissues Organs. 2010;191(4):281-8. doi: 10.1159/000272316 PMID: 20051666.
30. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 2009;15(21):6541-50. doi: 10.1158/1078-0432. CCR-09-0695 PMID: 19861460.
31. Lind DS. Arginine and cancer. J Nutr. 2004;134(10 Suppl):2837S-41S; discussion 53S. PMID: 15465796.
32. Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, Agron S, et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature. 2015;527(7578):379-83. doi: 10.1038/nature15529 PMID: 26560030; PubMed Central PMCID: PMCPMC4655447.
33. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100(4):826-33. doi: 10.1002/cncr.20057 PMID: 14770441.
34. Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspasedependentapoptosis. Cell Death Dis. 2012;3:e342. doi: 10.1038/cddis.2012.83 PMID: 22764101; PubMed Central PMCID: PMC3406582.
35. Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19(11):2861-72. doi: 10.1158/1078-0432. CCR-12-2641 PMID: 23549872.
36. Shan YS, Hsu HP, Lai MD, Yen MC, Chen WC, Fang JH, et al. Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. Sci Rep. 2015;5:9783. doi: 10.1038/srep09783 PMID: 25928182; PubMed Central PMCID: PMCPMC4415574.
37. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 1992;52(9):2610-5. PMID: 1568228.
38. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol. 1998;275(1 Pt 1):L165-71. PMID: 9688948.
39. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994;57(6):1395-401. PMID: 8010779.
40. Watson PM, Miller SW, Fraig M, Cole DJ, Watson DK, Boylan AM. CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J RespirCell Mol Biol. 2008;38(6):671-8. doi: 10.1165/rcmb.2007-0205OC PMID: 18218995; PubMed Central PMCID: PMC2396246.
41. Popescu NC, Chahinian AP, DiPaolo JA. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res. 1988;48(1):142-7. PMID: 3334988.
42. Broaddus VC, Dansen TB, Abayasiriwardana KS, Wilson SM, Finch AJ, Swigart LB, et al. Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem. 2005;280(13):12486-93. PMID: 15615731.
43. Harasawa R, Mizusawa H, Nozawa K, Nakagawa T, Asada K, Kato I. Detection and tentative identification of dominant mycoplasma species in cell cultures by restriction analysis of the 16S-23S rRNAintergenic spacer regions. Res Microbiol. 1993;144(6):489-93. PMID: 7910696.
44. Barczak A, Rodriguez MW, Hanspers K, Koth LL, Tai YC, Bolstad BM, et al. Spotted long oligonucleotide arrays for human gene expression analysis. Genome Res. 2003;13(7):1775-85. doi: 10.1101/gr.1048803 PMID: 12805270; PubMed Central PMCID: PMCPMC403751.
45. Cleveland WS. Robust Locally Weighted Regression and Smoothing Scatterplots. Journal of the American Statistical Association 1979;74(368):829-36.
46. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30(4):e15. PMID: 11842121; PubMed Central PMCID: PMC100354.
47. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25(4):402-8. doi: 10.1006/meth.2001.1262 PMID: 11846609.